The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
April 26th 2024
Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.
Two New Studies Report Significant Benefit With CDK4/6 Inhibitors in Advanced Breast Cancer
September 29th 2019Treatment with a CDK4/6 inhibitor plus fulvestrant found to improve overall survival in women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer.
Read More
Pharmacist/Nurse Led Clinic Eases Care for Melanoma
September 29th 2019A pharmacist and nurse led non-medical prescribing clinic that was focused on side effect management and survivorship support for patients with melanoma helped to improve common every-day pressure seen in a medical day unit and improved overall patient experience.
Read More
Considerations for Oncology Pharmacists Managing Patients on PARP Inhibitors
September 28th 2019At the ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the role of oncology pharmacists in managing the treatment of patients with ovarian cancer.
Read More
New Clinical Data Highlight Effect of PARP Inhibitors on Ovarian Cancer Treatment
September 28th 2019At ESMO Congress 2019, Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital, discussed the latest practice-changing clinical data results involving PARP inhibitor therapy in ovarian cancer.
Read More
Provider Partnerships: The Leading Strategy for Health System Specialty Pharmacy Success
August 27th 2019An upcoming webinar by Trellis Rx on Wednesday, September 18, will offer a firsthand look into how to accelerate the growth of your specialty pharmacy program by building strong provider partnerships.
Read More
First-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung Cancer
February 5th 2018The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) compared with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).
Read More